Posts Tagged: bio


IP Protection Critical for BioPharma Given Number, Cost and Complexity of Clinical Trials

Biopharmaceutical innovation is difficult, expensive, time-consuming, and risky. More so now than ever. A 2014 study by Tufts University’s Center for the Study of Drug Development calculated …
By Dr. Kristina Lybecker
6 months ago 9

Jim Greenwood to Chair BIO Ventures for Global Health Board of Directors

BIO Ventures for Global Health (BVGH) announced that Jim Greenwood, President and CEO of the Biotechnology Innovation Organization (BIO) has been elected as the new BVGH Board …
By Press Releases
11 months ago 0

Will More Regulation Create Cheaper Drugs?

The idea of reducing drug prices through more government control is always simmering on the backburner and doesn’t require much to bring it to a full …
By Joseph Allen
1 year ago 12

BIO, PhRMA lobby for IPR fix to insulate their patents from challenge

Greenwood and Castellani will have two major problems as they seek relief. First, the IPR provisions do not include a standing requirement, which means that anyone can …
By Gene Quinn
1 year ago 7

Mixed Reviews for the PATENT Act in the Senate

Microsoft applauded the introduction of the PATENT Act. Universities seem to be on the fence, recognizing that the Senate alternative is an improvement, but likely to support …
By Gene Quinn
2 years ago 8

In Defense of Patents and Licensing: Why the Newest Attack is Bogus

Fortunately, a new study showing that academic patent licensing contributed more than $1 trillion to the U.S. economy over eighteen years blows the stuffing right out of …
By Joseph Allen
2 years ago 1

Innovator Concerns Grow over Innovation Act

Calling the Innovation Act fast-tracked doesn't do justice to what is really happening. The Innovation Act was only officially introduced on October 23, 2013, and the Committee has not …
By Gene Quinn
3 years ago 7

The U.S. Government’s Position in ACLU v. Myriad Genetics: Observations on a ‘Waste of Time and Space’

So maybe the Federal Circuit won’t find “preemption” to be useful in deciding this appeal; we’ll know soon enough. I, for one, can’t make …
By Hans Sauer
4 years ago 6

BIO Hails House Passage of FDA Safety and Innovation Act

It will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It will …
By Jim Greenwood
4 years ago 0

University Licensing and Biotech IPRs Good for the Economy

Earlier in the week BIO also unveiled another report it commissioned and which was authored by Lori Pressman, David Roessner, Jennifer Bond, Sumiye Okubo, and Mark Planting. …
By Gene Quinn
4 years ago 1

BIO Lauds Senate Passage of User Fee Package

The inclusion of an enhanced Accelerated Approval pathway, crafted by Senator Kay Hagan (D-NC), will help expedite the development of modern, targeted, and personalized therapies for patients …
By Gene Quinn
5 years ago 0

Insiders React to Supreme Court Prometheus Decision

Just over three weeks ago the United States Supreme Court issued a decision in Mayo Collaborative Services v. Prometheus Laboratories, which sent much of the patent world …
By Gene Quinn
5 years ago 25

Industry Urges Congress to Continue Renewable Fuel Standard

While many people believe that alternative energy is at least several decades away, what is clear is that if we do not set out about making that …
By Gene Quinn
6 years ago 1

House Patent Reform Bill is in Need of Reform, BIO to Oppose

BIO has consistently praised House Judiciary Committee Chairman Lamar Smith (R-TX) for his introduction of a comprehensive patent reform bill similar to the bill adopted by the …
By Jim Greenwood
6 years ago 4

Ethical Issues: Staying in the Frying Pan and out of the Fire

In the situation where there is a joint research collaboration everything is fine, people are happy and hope springs eternal right up until that moment when everything …
By Gene Quinn
6 years ago 1